BioSpace News Archive

Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion.

Boundless Bio, a clinical-stage oncology company interrogating extrachromosomal DNA biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced financial results for the first quarter of 2024 and highlighted recent progress.

Legend Biotech Corporation, a global leader in cell therapy, reported its first quarter 2024 unaudited financial results and key corporate highlights.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announces that it held a conference for 75 oncologists and coordinators who are conducting the pivotal Phase 3 advanced liver cancer study, to accelerate patient enrolment.

Ajax Therapeutics, Inc. announced that it has received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 1clinical study of AJ1‑11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.

Precision BioSciences, Inc., an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Newron Pharmaceuticals S.p.A. presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine.

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended March 31, 2024 and provided a business update.

Recce Pharmaceuticals Ltd. today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.

Cabaletta Bio, Inc. today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY.